Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:605199'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.17 Med: 1.69 Max: 12.31
Current: -2.98
During the past 10 years, the highest Debt-to-EBITDA Ratio of Hainan Huluwa Pharmaceutical Group Co was 12.31. The lowest was -9.17. And the median was 1.69.
SHSE:605199's Debt-to-EBITDA is ranked worse than 100% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:605199: -2.98
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hainan Huluwa Pharmaceutical Group Co Debt-to-EBITDA Related Terms
Hainan Huluwa Pharmaceutical Group Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hainan Huluwa Pharmaceutical Group Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hainan Huluwa Pharmaceutical Group Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) has a Debt-to-EBITDA of -3.45 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hainan Huluwa Pharmaceutical Group Co. According to the industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #999999 out of 678 companies in the Drug Manufacturers industry.
Is Hainan Huluwa Pharmaceutical Group Co's Debt-to-EBITDA too high?
Hainan Huluwa Pharmaceutical Group Co's current Debt-to-EBITDA is -3.45. Based on the distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #999999 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hainan Huluwa Pharmaceutical Group Co has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hainan Huluwa Pharmaceutical Group Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #999999 out of 678 companies for Debt-to-EBITDA. This places Hainan Huluwa Pharmaceutical Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hainan Huluwa Pharmaceutical Group Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hainan Huluwa Pharmaceutical Group Co's current Debt-to-EBITDA is -3.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hainan Huluwa Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.46, compared to a current price of ¥5.77 — trading 29.4% above its estimated fair value. The current Debt-to-EBITDA is -3.45. Hainan Huluwa Pharmaceutical Group Co's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hainan Huluwa Pharmaceutical Group Co (SHSE:605199), the current Debt-to-EBITDA is -3.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Overvalued in 2026?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥5.77 is trading 29.4% above its estimated GF Value™ of ¥4.46.
GuruFocus considers Hainan Huluwa Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:605199:
Debt-to-EBITDA: -3.45
GF Value™: ¥4.46 vs. price of ¥5.77 (29.4% above fair value)
No single metric tells the full story. See the SHSE:605199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.
51GF Score
Get the complete analysis for SHSE:605199
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605199 has been successfully added to your 
